NC
FPRX

Nexthera Capital’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Nexthera Capital’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-20,000
Closed -$813K – 43
2016
Q1 		$813K Sell
20,000
-1,500
-7% -$51.6K 0.84% 22
2015
Q4 		$892K Buy
+21,500
New +$721K 1.27% 13

Other funds holding FPRX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Nexthera Capital's FPRX Position: Q2 2016 in Review

Nexthera Capital sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2016, closing a stake of 20,000 shares — an estimated $813K sold.

Nexthera Capital first reported a position in FPRX in Q4 2015 and held it in 2 quarters. The position peaked at $892K in Q4 2015. 170 funds tracked by Wall St. Rank hold FPRX as of Q2 2016.

  • Nexthera Capital reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • Nexthera Capital sold 20,000 Five Prime Therapeutics, Inc. shares in Q2 2016, an estimated $813K.
  • Nexthera Capital first reported a position in Five Prime Therapeutics, Inc. in Q4 2015 and held it in 2 quarters.
  • Nexthera Capital's Five Prime Therapeutics, Inc. position peaked at $892K in Q4 2015.
  • 170 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2016.

Based on Nexthera Capital's 13F filing for Q2 2016, filed 15 Aug 2016.